Article

Glaucoma device studied

Ivantis is expanding multiple randomized controlled trials of its intracanalicular scaffold (Hydrus) for the treatment of primary open-angle glaucoma using $17 million in funding from New Enterprise Associates (NEA) and Delphi Ventures.

Irvine, CA-Ivantis is expanding multiple randomized controlled trials of its intracanalicular scaffold (Hydrus) for the treatment of primary open-angle glaucoma using $17 million in funding from New Enterprise Associates (NEA) and Delphi Ventures.

The eyelash-sized device, which recently received CE mark approval, is placed through a minimally invasive, microsurgical procedure and is designed to reduce IOP by reestablishing a patient’s natural outflow pathway. It relies on a two-fold mechanism of action that creates a large opening through the trabecular meshwork and then dilates and scaffolds Schlemm’s canal.

“All signals are that this technology can potentially revolutionize glaucoma treatment worldwide,” said John Nehra, special partner at NEA.

The first patient has enrolled in the company’s first international randomized controlled trial, Hydrus II, in Madrid, Spain. The company expects to start two additional randomized controlled trials this year.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.